Google Ventures CEO Maris on A.I., Theranos, Biotech & VC

The transcript discusses the intersection of AI and biotech, highlighting the potential of AI in cancer diagnostics and the challenges of liquid biopsy technology. It covers the ethical considerations of gene editing, the downfall of Theranos, and the fluctuating biotech market. Leadership changes in tech companies like Nest and Uber are examined, along with the impact of political leadership on Silicon Valley. The conversation emphasizes the importance of informed voting and rational investment strategies.

What is the significance of early cancer detection technologies like GRAIL?

In what ways can gene editing be beneficial despite its potential risks?

How should investors approach the current state of the biotech market?